



This is a repository copy of *Testing and cancer diagnosis in general practice*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/221654/>

Version: Accepted Version

Article:

Bradley, S. orcid.org/0000-0002-2038-2056 and Watson, J. (2025) Testing and cancer diagnosis in general practice. BMJ Quality & Safety. ISSN 2044-5415

<https://doi.org/10.1136/bmjqs-2024-017921>

© 2025 The author(s). Except as otherwise noted, this author-accepted version of a journal article published in BMJ Quality & Safety is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Testing and cancer diagnosis in general practice

Stephen H. Bradley^{1, 2}

Jessica Watson^{3, 4} (Corresponding author)

¹ General Practitioner, York Street Practice, Leeds, LS9 8AA

² Senior Lecturer, School of Medicine and Population Health, University of Sheffield, S1 4DP

ORCID 0000-0002-2038-2056

³ General Practitioner, West Walk Surgery, Yate, BS37 4AX

⁴ NIHR Academic Clinical Lecturer, Centre for Academic Primary Care, University of Bristol, Bristol, UK, Bristol BS8 2PN

ORCID 0000-0002-8177-6438

Correspondence to Jessica Watson, Jessica.Watson@bristol.ac.uk

Healthcare systems worldwide, have for decades sought to prioritise prompt diagnosis of cancer as a means to improve outcomes. The gatekeeping role of general practitioners (GPs) that restricts access to testing and referral[1] along with their relatively lower propensity to use diagnostic tests[2] have been offered as partial explanations for the UK's consistently poor performance in cancer compared to other high income countries.[3]

In this issue of BMJ Quality and Safety, Akter and colleagues examined primary care investigations prior to a cancer diagnosis, using data on 53,252 patients and 1868 general practices from the 2018 English National Cancer Diagnostic Audit. [4] Grouping tests into four categories (any investigation, blood tests, imaging and endoscopy) the study demonstrated large variation in use of tests in general practice prior to diagnosis with cancer. Recorded characteristics of practices accounted for only a small proportion of this variation, suggesting the possibility that testing behaviours could be amenable change, for example, by encouraging greater uptake of particular tests in certain patient groups. Whether such a strategy would benefit patients is unknown and as the study reported on tests in aggregate, rather than the pertinent test for that particular cancer, no definitive judgment can be drawn regarding whether higher levels of testing in the pre-diagnosis period would have expedited diagnosis.

Akter et al found that the 'blood test' category was the test most frequently performed in those who were later diagnosed with cancer, with 23,422 out of 53,252 patients (44%) receiving such a test. Abnormalities on full blood count (FBC) are one (among other) criteria for further investigation or referral for gastrointestinal, endometrial, lung and haematological malignancies but testing with non-specific blood tests does not otherwise feature within NICE guidance for diagnosing cancer in general practice.[5] However, in some other situations FBC along with other tests like inflammatory markers may help inform decision making about whether to undertake further investigation or referral when faced with non-specific symptoms or particular uncertainty.[6]

Uncertain benefits from increases in general practice testing

Substantial increases in blood and imaging tests from general practice in the UK have been observed in recent decades, resulting in costs of around £2.8 billion in 2015, and around two hours of GPs' time per day to review results.[7] It is plausible that some of the improvements in specific outcomes such as cancer diagnosis that have been achieved over the same period,[3] could in part be linked to increased testing in general practice. For example, some observational studies have linked increased chest x-rays and endoscopies with improved outcomes for lung and upper gastrointestinal cancers respectively.[8,9] Yet, it seems highly uncertain that the huge costs and substantial harms resulting from increases in testing overall is warranted

There is also little reason to believe more frequent testing has enhanced patient experience or contributed to enhanced shared decision-making. A UK study examining general practice records of 2572 patients who received blood tests showed that in 47% there was no documented evidence that test results had been communicated.[10]

Diagnosis relies on using the right test

To achieve a diagnosis via testing a clinician will typically have had to select the appropriate test for the suspected cancer. Avoidable diagnostic delay can occur when testing or referral that is recommended by guidelines in response to particular symptoms, is not arranged.[11] Where clinicians successfully arrange recommended testing, GPs need to consider other pitfalls that can delay diagnosis. Since symptoms of many different cancers overlap, placing too much emphasis on a negative test result for one cancer type may engender misplaced reassurance. For example, a Faecal Immunochemical Test (FIT) could be one of several tests used in response to weight loss, but will not yield diagnosis if the cause was lung cancer. Particularly in the context of declining relational continuity of care, when patients may follow up test results with a doctor who hadn't requested the original test and taken the initial history, there is a risk that these follow up visits will only focus on conveying test results and providing reassurance rather than revisiting symptoms and reappraising if further testing is indicated. Even where the correct test has been selected, cancer tests have varying sensitivity, meaning patients who have false negative results must rely on the intuition of GPs to understand when to retest or refer despite negative tests.[12] GPs must consider these factors to avoid pitfalls in the diagnostic process.

Non-specific blood testing in cancer diagnosis

In the context of a clinician's intuition (sometimes termed 'gut feeling') of serious underlying disease, abnormalities in non-specific tests may raise the suspicion of cancer sufficiently to prompt further testing (e.g. chest x-ray prompted by thrombocytosis in a patient with tiredness) or lead to referral to diagnostic services commissioned to investigate for cancer in those with non-specific symptoms. However, the prospect that non-specific blood tests alone, such as inflammatory markers, FBC, Liver Function Tests and Urea and Electrolytes can be expected to expedite cancer diagnoses within current practice is not at all assured (Figure 1). In Australian General Practice, increased blood testing is observed seven months prior to colorectal cancer diagnoses and six months prior to lung cancer. The majority of those tested had abnormal results, but this in itself did not ensure prompt diagnosis, with the earliest abnormal results reported a median of 124 days before colorectal cancer diagnoses (IQR 32-229 days) and 190 days before lung cancer diagnoses (IQR 53-264).[13]

That increased testing is observed prior to cancer diagnoses has led to the suggestion that 'diagnostic windows' exist within which diagnosis could potentially be expedited. Within current practice remains the challenge of identifying which patients who have abnormal blood tests warrant further testing or referral, but emerging evidence suggests that information from these common tests can be combined with symptoms to help stratify risk of cancer. For example a raised inflammatory marker (C Reactive Protein) in patients with unintentional weight loss is associated with a risk of cancer diagnosis within 6 months of 8.3% (95% confidence intervals 6.3 to 10.7) for men aged 40-49 compared to a baseline risk for the same age group reporting unintentional weight loss of only 1.1% (95% confidence interval 1.0 to 1.2).[14] Important challenges would need to be overcome to operationalise such insights, including the need to consider multiple cancer types and the difficulty for GPs in recognising the risk conferred by the combination of symptoms and particular blood test results.

Blood tests are also not sufficient to rule out serious disease and may be a source of inappropriate reassurance, and possibly delay, since selection bias counterintuitively means that those with normal results have cancer risk that exceeds that of untested populations.[15] For example, elevated platelets (thrombocytosis) is known to indicate an increased risk of cancer, but since doctors choose who to test based on clinical concern, the one year cancer risk for men aged 40 or over with normal platelet count is substantial at 4.1% (95% CI = 3.4 to 4.9).[16]

Do increased volumes of testing lead to improved outcomes?

Observational studies have shown that patients attending practices that undertake more cancer referrals have improved survival.[17] Since referral for several cancer types is often contingent on concerning results from a triage test, such as FIT for colorectal cancer or CA 125 for ovarian cancer, it is plausible that increased levels of testing, for those with particular symptoms could also lead to improved outcomes.

Practices that undertake greater volumes of testing with non-specific blood tests prior to a cancer diagnosis probably undertake more testing overall. Abnormalities are common in such tests,[18] so identifying which patients with abnormalities require further investigation or referral, may actually be more challenging in organisations which undertake more non-specific tests. While Akter et al. demonstrated wide variation in testing, the existence of variation can not necessarily be assumed to be 'unwarranted'. Substantial increases in testing[7] in addition to evidence that recommended testing often does not take place,[10] suggest that complex patterns of over and under-testing are present. As Akter et al point out, research to determine what should be considered optimal levels of testing to facilitate comparison between services is needed. The difficulty in persuasively linking different levels of testing to patient outcomes and cost-effectiveness will be a barrier to the interpretation of such research. Even if achieved, clinicians will continue to face the difficulty of decision making for individual patients, a process which will continue to rely to some extent on subjective judgement. Such decision making may not necessarily be improved by putative optimal levels of testing, since such benchmarking will be more informative when considering whole practice populations rather than for individual patients.

Understanding testing behaviour that benefits patients

Akter et al. examined testing behaviour only in those who had been diagnosed with cancer and the reasons for testing were not available. However, high volume testing particularly with non-specific

blood tests used without clear understanding as to how their results should inform decision making could well be considered an indicator of lower quality care. Given the costs of such testing and the poor patient experience resulting from inadequate communication about tests, broad-brush policies or interventions to increase testing in general are unlikely to yield benefit overall. By consuming additional resources such measures might even lead to further deteriorations in access to care. Greater promise lies in focusing on developing interventions which increase specific investigations or referrals in appropriate patient groups, such as those with specific symptoms,[10,19] alongside further research to identify associations between testing rates and patient outcomes[7].

In the meantime, electronic health record vendors and bodies responsible for underused resources such as England's Diagnostic Imaging Dataset, should enable access to basic deidentified data on volumes of testing to facilitate reflection and understanding on how tests are currently being used within and between general practice services. In many instances such data is collected, but is not being effectively shared.

Figure 1: Diagnostic snakes and ladders in general practice. This figure is based on the board game snakes and ladders, in which players role a die to move their piece on the board. Landing on a square with a ladder allows the player to advance to a square nearer to the game's objective, whereas landing on a snake means the piece needs to be moved back nearer to the start of the game. Diagnostic tests in general practice may expedite cancer diagnosis (box 2), achieve diagnosis indirectly (box 4 leading to boxes 6 and 8) or prolong the diagnostic process (box 3 or box 4 leading to boxes 5 and 7 or box 9). Direct referral without testing (box 1) is recommended for some cancer symptoms. 'Blood test' refers to non-specific tests such as Full Blood Count or inflammatory markers. 'Cancer test' refers to triage tests used in general practice that can lead to referral for a specific suspected cancer such as chest x-ray (lung), cancer antigen 125 (ovarian), prostate specific antigen (prostate), Faecal Immunochemical Test (colorectal) or ultrasound (endometrial).

Competing interests: SHB has undertaken observational research examining lung cancer outcomes and volume of chest x-rays undertaken by general practices, which is currently under peer-review.

Acknowledgements: The authors wish to thank Prof Willie Hamilton for comments which helped us to improve this editorial.

Contributor statement: Stephen Bradley drafted the initial manuscript with revisions contributed by Jessica Watson. Stephen Bradley is the guarantor.

Funding statement: Not applicable

References

1. Vedsted P & Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. *Br J Gen Pract*. 2011 Aug; 61(589): e508–e512.
2. Rose PW, Rubin G, Perera-Salazar R et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. *BMJ Open* 2015;5:e007212

3. Arnold M, Rutherford MJ, Bardot A. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol*. 2019;20(11):1493-1505.
4. Akter N. Variation in the use of primary care led investigations prior to a cancer diagnosis: analysis of the National Cancer Diagnosis Audit. *BMJQS*-2024-017264.R1
5. Suspected cancer: recognition and referral. NICE guideline [NG12]. National Institute of Health and Care Excellence. 2023. <https://www.nice.org.uk/guidance/ng12> (accessed 29 September 2024)
6. Watson J, Mounce L, Bailey SER, Cooper SL, Hamilton W. Blood markers for cancer. *BMJ* 2019;367:l5774
7. O'Sullivan J, Stevens S, Hobbs FDR et al. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. *BMJ* 2018;363:k4666
8. Kennedy MPT, Cheyne L, Darby M et al. Lung cancer stage-shift following a symptom awareness campaign. *Thorax* 2018;73(12):1128-1136.
9. Shawihdi M, Thompson E, Kapoor N. Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. *Gut* 2014;63(2):250-61.
10. Watson J, Whiting PF, Salisbury C. Blood tests in primary care: A qualitative study of communication and decision-making between doctors and patients. *Health Expect* 2022;25(5):2453-2461
11. Koo MM, Mounce LTA, Rafiq M, et al. Guideline concordance for timely chest imaging after new presentations of dyspnoea or haemoptysis in primary care: a retrospective cohort study. *Thorax* 2024;79:236-244
12. Bradley SH, Nicholson BD, Funston G. Interpreting negative test results when assessing cancer risk in general practice. *Br J Gen Pract* 2021; 71 (708): 298-299.
13. Rafiq M, Drosdowsky A, Solomon B. Trends in primary care blood tests prior to lung and colorectal cancer diagnosis-A retrospective cohort study using linked Australian data. *Cancer Med* 2024;13(14):e70006
14. Nicholson B D, Virdee P, Aveyard P, Price S J, Hobbs F D R, Koshiaris C et al. Prioritising primary care patients with unexpected weight loss for cancer investigation: diagnostic accuracy study (update) *BMJ* 2024; 387 :e080199 doi:10.1136/bmj-2024-080199
15. Watson JC, Bailey S, Hamilton F et al. Lessons from biases in electronic health record data: the importance of clinical vigilance with negative test results. *BMJ Rapid response*. Available: <https://www.bmj.com/content/361/bmj.k1479/rr-0> (accessed 05 November 2024)
16. Bailey SER, Ukoumunne OC, Shephard EA et al. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. *Br J Gen Pract* 2017; 67 (659): e405-e413.
17. Møller H, Gildea C, Meechan D et al. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. *BMJ* 2015;351:h510

18. Naugler C, Ma I. More than half of abnormal results from laboratory tests ordered by family physicians could be false-positive. *Can Fam Physician* 2018; 64 (3) 202-203
19. Wiering B, Lyratzopoulos G, Hamilton W, et al. Concordance with urgent referral guidelines in patients presenting with any of six 'alarm' features of possible cancer: a retrospective cohort study using linked primary care records. *BMJ Qual & Saf* 2022;31:579-589